Showing results (311-320 of 592) with videos related to
Sort By:
Pageof 60
Chest|December 15, 2006
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, et al.Cancer|August 4, 2005
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary treeAlain Gelibter, Paola Malaguti, Serena Di Cosimo, et al.Annals of Translational Medicine|November 26, 2015
Melanoma: oncogenic drivers and the immune systemNiki Karachaliou, Sara Pilotto, Cristina Teixidó, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2025
Complete Response to Lorlatinib in Lung Adenocarcinoma With EML4-ALK Fusion Variant (E6;A18): Case Report and Literature ReviewAntonio Vitale, Elisa De Paolis, Jacopo Russo, et al.Minerva Surgery|August 2, 2021
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysisArmando Orlandi, Sabatino D'Archi, Giovanna Garufi, et al.Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.Journal of Women'S Health (2002)|July 3, 2018
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer CenterMaria Vittoria Dieci, Cristina Ghiotto, Caterina Barbieri, et al.Frontiers in Oncology|March 29, 2021
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA AnalysisLoredana Urso, Grazia Vernaci, Jessica Carlet, et al.British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.Cancers|July 2, 2021
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical FeaturesAntonio Passaro, Silvia Novello, Diana Giannarelli, et al.Pageof 60